Storia in 2 fonti

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sanofi (NASDAQ:SNY)

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.

Raccontata da

biopharmadive.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sanofi (NASDAQ:SNY)

Sanofi halts riliprubart Phase 3 trial in CIDP after missing efficacy targets. Failure strengthens Argenx's Vyvgart dominance; its randomized-withdrawal design beats competitors' parallel-group trials—a methodological edge that creates market barriers in rare diseases.

originale

biopharmadive.com1 mese fa

Sanofi stops immune drug trial in latest research setback

The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.

Leggi questa versione →

Timeline cronologica

mercoledì 10 giugno 2026·biopharmadive.com
Sanofi stops immune drug trial in latest research setback
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.
giovedì 11 giugno 2026·benzinga.com
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sanofi (NASDAQ:SNY)
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.